Literature DB >> 17224243

A subgroup of spinocerebellar ataxias defective in DNA damage responses.

N Gueven1, P Chen, J Nakamura, O J Becherel, A W Kijas, P Grattan-Smith, M F Lavin.   

Abstract

A subgroup of human autosomal recessive ataxias is also characterized by disturbances of eye movement or oculomotor apraxia. These include ataxia telangiectasia (A-T); ataxia telangiectasia like disorder (ATLD); ataxia oculomotor apraxia type 1 (AOA1) and ataxia oculomotor apraxia type 2 (AOA2). What appears to be emerging is that all of these have in common some form of defect in DNA damage response which could account for the neurodegenerative changes seen in these disorders. We describe here sensitivity to DNA damaging agents in AOA1 and evidence that these cells have a defect in single strand break repair. Comparison is made with what appears to be a novel form of AOA (AOA3) which also shows sensitivity to agents that lead to single strand breaks in DNA as well as a reduced capacity to repair these breaks. AOA3 cells are defective in the DNA damage-induced p53 response. This defect can be overcome by incubation with the mdm2 antagonists, nutlins, but combined treatment with nutlins and DNA damage does not enhance the response. We also show that AOA3 cells are deficient in p73 activation after DNA damage. These data provide further evidence that different forms of AOA have in common a reduced capacity to cope with damage to DNA, which may account for the neurodegeneration observed in these syndromes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224243     DOI: 10.1016/j.neuroscience.2006.12.010

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

Review 1.  Epigenetic principles and mechanisms underlying nervous system functions in health and disease.

Authors:  Mark F Mehler
Journal:  Prog Neurobiol       Date:  2008-10-17       Impact factor: 11.685

Review 2.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 3.  Molecular underpinnings of Aprataxin RNA/DNA deadenylase function and dysfunction in neurological disease.

Authors:  Matthew J Schellenberg; Percy P Tumbale; R Scott Williams
Journal:  Prog Biophys Mol Biol       Date:  2015-01-29       Impact factor: 3.667

4.  DNA-PK and P38 MAPK: A Kinase Collusion in Alzheimer's Disease?

Authors:  Jyotshna Kanungo
Journal:  Brain Disord Ther       Date:  2017-05-01

5.  Genetic interactions between HNT3/Aprataxin and RAD27/FEN1 suggest parallel pathways for 5' end processing during base excision repair.

Authors:  James M Daley; Thomas E Wilson; Dindial Ramotar
Journal:  DNA Repair (Amst)       Date:  2010-04-15

6.  Role of polymerase β in complementing aprataxin deficiency during abasic-site base excision repair.

Authors:  Melike Cağlayan; Vinod K Batra; Akira Sassa; Rajendra Prasad; Samuel H Wilson
Journal:  Nat Struct Mol Biol       Date:  2014-04-28       Impact factor: 15.369

Review 7.  DNA repair deficiency and neurological disease.

Authors:  Peter J McKinnon
Journal:  Nat Rev Neurosci       Date:  2009-01-15       Impact factor: 34.870

Review 8.  Polynucleotide kinase-phosphatase (PNKP) mutations and neurologic disease.

Authors:  Lavinia C Dumitrache; Peter J McKinnon
Journal:  Mech Ageing Dev       Date:  2016-04-26       Impact factor: 5.432

Review 9.  Do all of the neurologic diseases in patients with DNA repair gene mutations result from the accumulation of DNA damage?

Authors:  P J Brooks; Tsu-Fan Cheng; Lori Cooper
Journal:  DNA Repair (Amst)       Date:  2008-03-12

10.  CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response.

Authors:  Olivier J Becherel; Burkhard Jakob; Amy L Cherry; Nuri Gueven; Markus Fusser; Amanda W Kijas; Cheng Peng; Sachin Katyal; Peter J McKinnon; Junjie Chen; Bernd Epe; Stephen J Smerdon; Gisela Taucher-Scholz; Martin F Lavin
Journal:  Nucleic Acids Res       Date:  2009-12-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.